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Summary
TAS-117 is a potent and selective allosteric pan-v-akt murine thymoma viral oncogene homolog (Akt) inhibitor. We conducted a
single-arm single-center phase 2 study of TAS-117 in heavily treated patients with tumors refractory to systemic chemotherapy
and harboring phosphatidylinositol 3-kinase (PI3K)/Akt mutations. Patients with gastrointestinal (GI) cancers were orally ad-
ministered 16 mg TAS-117 daily, and those with non-GI tumors were administered 24 mg on a 4 days on/3 days off schedule.
The primary endpoint was overall response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-
free survival (PFS), overall survival (OS), PFS ratio, safety, and tolerability. Thirteen patients were enrolled: eight with non-GI
(breast, ovarian, endometrial, and non-small cell lung) and five with GI (colon, rectal, gastric, and gallbladder) cancers. Ten
patients were treated with TAS-117 after ≥ 4 lines of therapy. Twelve patients showed PIK3 catalytic subunit alpha (PIK3CA)
mutations; one harbored an Akt1E17K mutation. The median treatment duration was 1.4 months; the median number of treatment
cycles was 2. The ORRwas 8%, and DCRwas 23%. The median PFS and OSwere 1.4 and 4.8 months, respectively. Grade 3–4
treatment-related adverse events were anorexia (grade 3, 8 %) and hyperglycemia (grade 3, 8 %; grade 4, 8 %).Grade 3–4
treatment-related adverse events occurred in 27% of grade 3 anorexia (9%) and hyperglycemia (grade 3, 8 %; grade 4, 9\%).
TAS-117 showed limited antitumor activity and manageable toxicity. Clinical efficacy was observed in patients with ovarian
cancer harboring PIK3CA E545K mutations and in patients with breast cancer harboring PIK3CA H1047R and Akt1E17K
mutations.
Trial registration: This study was retrospectively registered with ClinicalTrial.gov (NCT03017521 on January 11, 2017).
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Background
The phosphatidylinositol 3-kinase (PI3K)/v-akt murine
thymoma viral oncogene homolog (Akt)/mammalian target
of rapamycin (mTOR) signaling pathway plays a role in cell
proliferation, cell cycle, apoptosis, and cancer cell metabolism
[1]. The dysregulation of this pathway has been associated
with various types of cancer [2]. Therefore, inhibiting the
PI3K/Akt/mTOR pathway using targeted agents may clinical-
ly benefit patients harboring mutations in genes associated
with this pathway.
Over the past few years, more than 40 novel compounds
targeting the PI3K/Akt/mTOR pathway have been developed
[3]. However, only few agents such as mTOR inhibitors
(temsirolimus and everolimus) and PI3K inhibitors (idelalisib,
a δ-specific PI3K inhibitor; copanlisib, a PI3K inhibitor pre-
dominantly active against PI3K-α and PI3K-δ; and alpelisib,
an α-specific PI3K inhibitor) have been approved by the
United States Food and Drug Administration (FDA) [4–9].
Although FDA-approved, allosteric mTOR inhibitors such
as temsirolimus and everolimus have shown low objective
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response rates when administered as monotherapies [4, 6].
With the exception of copanlisib, pan-PI3K inhibitors show
intolerable toxicities owing to their broad spectrum molecular
activities [10]. Other agents have failed because of poor effi-
cacy, high toxicity, or a lack of reliable predictive biomarkers
[11].
Several preclinical studies using cell lines and xenografts
have shown that targeting the downstream Akt pathway re-
duces cell proliferation in multiple tumor cell lines [12]. Akt
activation results from abnormalities in upstream regulators
including (1) upstream activation or gene amplification of
receptor tyrosine kinases, (2) amplification of or mutations
in the PI3K catalytic subunit alpha (PIK3CA) gene encoding
the p110α catalytic subunit of PI3K, or (3) gene silencing of
phosphatase and tensin homolog (PTEN), a tumor suppressor
gene that negatively regulates the PI3K pathway [13].
TAS-117 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan)
is a highly potent and selective oral allosteric Akt inhibitor that
shows high affinity for all three isoforms (Akt1, 2, and 3) [14].
It inhibits the proliferation of human cancer cell lines in vitro,
including breast, endometrial, lung, and ovarian cancer cells
[15]. Furthermore, tumor cell lines sensitive to TAS-117 in-
clude those with Akt2 and human epidermal growth factor
type 2 (HER2) gene amplification, PI3K mutations, and
PTEN loss. In a nude mouse xenograft model, the daily ad-
ministration of TAS-117 caused significant dose-dependent,
antitumor effects. A phase 1, all-comers study of TAS-117
including 60 patients with evaluable advanced solid tumors
showed promising objective responses, especially in patients
with ovarian cancer. In addition, TAS-117 showed a manage-
able safety profile across patients with all cancer types. The
recommended phase 2 doses (RP2Ds) were 16 mg daily and
24 mg, 4 days on/3 days off, because of the dose-limiting
toxicity of maculopapular rash [14]. Therefore, we conducted
a phase 2 study of TAS-117 in patients with advanced solid
tumors harboring PI3K/Akt gene aberrations as part of the
Korea-Biomarker-driven multi-arm drug-screening, knowl-
edge and evidence-generating targeted trial (K-BASKET tri-
al). In this study, we report the efficacy and safety of TAS-117
in multiple cancer types that are refractory to standard
treatments.
Methods
Study design and patients
This phase 2 trial of TAS-117 is part of the K-BASKET trial
conducted at the Yonsei Cancer Center, Korea. The trial was
registered at ClinicalTrials.gov (NCT03017521). Eligibility
criteria included patients with histologically or cytologically
confirmed recurrent or advanced solid cancers with PI3K/Akt
gene aberrations identified via next-generation sequencing
(NGS), with one of the following mutations: (1) PIK3CAmu-
tations in E542X, E545K, Q546X, Q546X, or H1047X; (2)
AktE17K; or (3) Akt1/Akt2 amplifications. Other eligibility
criteria included previous standard treatment failure; at least
one measurable lesion according to the Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 criteria [16];
Eastern Cooperative Oncology Group (ECOG) performance
status score of 0 (fully active) to 1 (ambulatory and capable of
self-care); ability to receive medication orally without feeding
tube; life expectancy ≥ 60 days; adequate hematological, he-
patic, and renal function; fasting serum glucose ≤ 160 mg/dL;
glycosylated hemoglobin ≤ 8.0 %; low-density lipoproteins ≤
190 mg/dL; and triglycerides ≤ 300 mg/dL. The key exclusion
criteria included prior treatments targeting PI3K/Akt gene ab-
errations, retinopathy requiring treatment, and concurrent
treatment requiring steroids.
All authors followed Good Clinical Practice, and the study
was conducted according to the principles of the Declaration
of Helsinki. All patients enrolled provided written informed
consent. The trial was conducted in accordance with the
CONsolidated Standards of Reporting Trial (CONSORT),
and the protocol was approved by the Institutional Review
Board of Severance Hospital (IRB 4-2016-0743).
Study treatment
The study was conducted over 21-day treatment cycles. The
doses were based on results from the phase 1 trial, and the
RP2D was calculated according to tumor types (gastrointesti-
nal [GI] or non-GI tumors). Patients with GI tumors received
16 mg of TAS-117 daily under fasting conditions (1 h before
or 2 h after a meal), and patients with non-GI cancers received
24mg, 4 days on/3 days off. Dose interruptions, up to 21 days,
and dose reductions, to 12 mg (level − 1) and 8 mg (level − 2)
for GI cancers and 20 mg (level − 1) and 16 mg (level − 2)
non-GI cancers, were allowed. Treatment was continued until
disease progression, the occurrence of an unacceptable ad-
verse event (AE), drug interruption for > 21 days, > 2 dose
reductions, or withdrawal.
Assessments
Disease status was assessed using contrast-enhanced comput-
ed tomography at the baseline, every 6 weeks, and at progres-
sion according to RECIST v1.1. Tumor markers such as
carcinoembryonic antigen, carbohydrate antigen 19 − 9, can-
cer antigen-125, and cancer antigen 72 − 4 were assessed ac-
cording to tumor type and represented as the percent change
from the baseline. AEs and treatment-related AEs were eval-
uated throughout treatment and 30 days after the end of treat-
ment using the National Cancer Institute Common
Terminology Criteria for Adverse Events v4.3.
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NGS was performed using archival tumor specimens ob-
tained prior to TAS-117 treatment. An in-house panel (Cancer
Master), a pan-cancer NGS platform that includes 524 genes
and was developed in the Department of Pathology and Song-
Dang Institute for Cancer Research, was used to assess co-
existing mutations, including single nucleotide variants, inser-
tion–deletions, and copy number variants.
Statistics
To apply a one-sided significance level of 5 % and 90 %
power, 25 patients were required to reject the null hypoth-
esis that the upper bound of the 95 % confidence interval
(CI) of the overall response rate (ORR) was < 25 %.
Assuming a 20 % drop out rate, the final sample size was
30 patients for both GI cancers and non-GI cancers in a 24-
month enrolment period.
All patients receiving ≥ 1 dose of TAS-117 were evaluated
for endpoints related to efficacy and AEs. The primary end-
point was ORR, according to RECIST v1.1. The secondary
endpoints included disease control rate (DCR), progression-
free survival (PFS), overall survival (OS), PFS ratio, and the
safety and tolerability of TAS-117. Exploratory endpoints in-
cluded clinical responses to TAS-117 according to PI3K/Akt
aberration subtypes and the identification of co-existing mu-
tations associated with sensitization or resistance to PI3K/Akt
aberrations.
The ORRwas defined as the proportion of patients with the
best overall complete or partial response. The Kaplan–Meier
method was used to estimate median PFS and OS. Safety and
tolerability were analyzed using descriptive statistics.
Analyses were conducted using SPSS statistical software
v25 (IBM Corp., Armonk, NY, USA) and GraphPad Prism
8 (GraphPad Software, Inc., San Diego, CA, USA).
Results
Patients
Between November 21, 2017 and June 27, 2019, 13 patients
with advanced solid tumors harboring PI3K/Akt gene aberra-
tions were screened and enrolled. The baseline characteristics
are listed in Table 1. The median age was 53 years (range, 34–
71), and 12 patients (92%) were female. The ECOG perfor-
mance status was 0 for eight patients (62%).
Eight patients with non-GI cancers were enrolled, includ-
ing breast (n = 4, 31%), ovarian (n = 2, 15%), endometrial
(n = 1, 8%), and non-small cell lung cancer (NSCLC; n = 1,
8 %). In addition, five patients with GI cancers, including
colon (n = 2, 15%), rectal (n = 1, 8%), gastric (n = 1, 8%),
and gallbladder cancer (n = 1, 8%), were enrolled. With the
exception of three patients who received TAS-117 as second-
or third-line treatment, most of the patients (n = 10, 77 %)
treated with TAS-117 had already received more than three
lines of treatment. In addition, 46% (n = 6) and 84% (n = 11)
of patients had Royal Marsden Scores (RMS) and Gustave
Roussy Immune Scores (GRIm-Scores) of 0 and 1,
Table 1 Baseline characteristics of patients








Breast cancer 4 (31%)
Ovarian cancer 2 (15%)
Endometrial cancer 1 (8%)
Colon cancer 2 (15%)
Rectal cancer 1 (8%)
Gastric cancer 1 (8%)
Gallbladder cancer 1 (8%)
NSCLC 1 (8%)






















Abbreviations: ECOG, Eastern Cooperative Oncology Group; GRIm-
Score, Gustave Roussy Immune Score
*An ECOG performance status score 0 means that the patient is fully
active and 1 means that the patient is restricted in physically strenuous
activity but ambulatory
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respectively. Most patients had two or more metastatic organs
(n = 12, 92 %). Twelve patients showed mutations in
PIK3CA: E542K (n = 2, 15%), E545A (n = 1, 8%), E545K
(n = 4, 31%), H1047R (n = 4, 31%), and Q546K (n = 1, 8%),
and one patient harbored Akt1E17K mutations (Supplementary
Table S1).
Antitumor activity
At the end of the data collection period on February 19, 2020,
the median follow-up duration was 6.6 months (range, 1–18.1
months). The median duration of treatment was 1.4 months
(range, 0.4–3.2 months), and the median number of treatment
cycles was 2 (range, 1–5; Supplementary Table S2). Of the 13
patients, none showed a complete response, one patient with
ovarian cancer showed a confirmed partial response, and two
patients with breast cancer had stable disease (Fig. 1). Eleven
patients were assessed via radiology, but two patients did not
have radiological assessments because of rapid clinical
deterioration.
The ORR and DCR of TAS-117 were 8 % (n = 1) and
23 % (n = 3), respectively (Supplementary Table S3). All
responses were achieved in patients with non-GI tumors,
and the median t ime to response was 6 weeks
(Supplementary Figure S1A). One patient with metastatic
ovarian cancer harboring PI3Kα E545K mutations
showed a 39 % tumor reduction at 6 weeks (data not
shown). However, this decrease in tumor burden was not
maintained over subsequent assessments, and the patient
showed progression in non-target lesions and an increase
in tumor markers at 12 and 18 weeks (Supplementary
Figure S1B). The two patients with breast cancer who
achieved stable disease condition (n = 2, 15 %) and
harbored Akt1E17K and PI3Kα H1047R mutations showed
disease progression at 12 weeks, associated with an in-
crease in non-target lesions. Other patients with breast
cancer (n = 2, 15 %), ovarian cancer (n = 1, 8 %), GI can-
cer (n = 5, 38 %), and NSCLC (n = 1, 8 %) showed pro-
gression at the first response evaluation, as depicted in
both the spider and swimmer plot (Supplementary
Figure S1 and Fig. 2, respectively). In eight patients ex-
pressing tumor markers, there was an increase in the per-
centage of tumor markers at 6 weeks in six patients,
which did not correlate with radiological responses
(Supplementary Figure S1B). A summary of the best re-
sponses according to PI3K/Akt aberrations is shown in
Supplementary Table S5.
The median PFS was 1.4 months (95 % CI: 1.2–1.6
months) for TAS-117 treatment (Fig. 3a, Supplementary
Figure S2). PFS values prior to (PFS 1) and after (PFS 3)
TAS-117 treatment were 2.6 (95 % CI: 1.7–3.5 months)
and 1.2 months (95 % CI: 0–4.7 months), respectively.
PFS2/1 ratio > 1.3 and PFS3/2 ratio > 1.3 were both 0 %,
and PFS2/1 ≥ 1.2 ratio and PFS3/2 ≥ 1.2 ratio were 8 % and
23 %, respectively [17]. The median OS was 4.8 months
(95 % CI: 2.6–11.2 months; Fig. 3b). A univariate analysis
of treatment line (< 4 vs. ≥ 4), RMS (0 or 1 vs. ≥ 2), GRIm-
Score (0 or 1 vs. ≥ 2), and number of metastatic lesions (< 2
vs. ≥ 2) showed that there was no statistical significance in
either PFS or OS (Supplementary Table S6).
Nine patients had disease progression, two experienced
adverse events, one withdrew from the study, and one
discontinued treatment owing to the physician’s decision. Of
the 11 evaluable patients, most showed progression in previ-
ous target lesions (n = 9, 69 %), such as the lungs (n = 6,






















Types of cancer Gastric Ovarian Breast Colon Rectal Gallbladder Endometrium Breast NSCLC Breast Ovarian
Line of treatment 9 4 6 4 5 2 4 4 4 5 3
PI3K/Akt aberrations E545K E545K H1047R Q546K E545K E545K H1047R H1047R E542K E17K* E545K
Best % change in tumor volume +174 +77 +35 +24 +23 +14 +13 -7 -7 -12 -39
Best % change in tumor markers +20 NA +100 NA +100 NA +70 NA NA +100 -60
Fig. 1 Waterfall plot depicting best percent changes in target tumor
burden. All patients harbored PI3K aberrations, except for patients with
breast cancer harboring AKT E17K* mutations. Two patients with
clinical progression were excluded from this graph. Seven subjects did
not undergo subsequent follow-up of tumor markers. Abbreviations:
NSCLC, non-small cell lung cancer; NGG, next-generation sequencing;
PI3K/Akt, phosphatidylinositol 3-kinase/protein kinase B; NA, not appli-
cable (no follow-up of tumor markers for assessment)
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(n = 4, 36%; Supplementary Table S7). One patient devel-
oped a new site of metastasis in the liver (n = 1), and one
patient developed new lesions in both the common bile duct
and pancreas. The two patients without radiological assess-
ments also showed clinical progression. A one-way analysis
of variance (ANOVA) showed no statistical difference in pro-
gression between organs (p = 0.076; Supplementary
Figure S3).
At progression, six patients (46 %) received subsequent
treatment, including cytotoxic chemotherapy (n = 3, 23%),
immunotherapy (n = 2, 15 %), and targeted agents (n = 1,
8 %; Supplementary Table S2). At the time of analysis,11
patients had died, one patient was receiving best supportive
care, and one patient was receiving subsequent chemotherapy
(Fig. 2).
Co‐existing mutations
In this study, patients with PI3K/Akt aberrations also har-
bo r e d d i v e r s e co - e x i s t i n g mu t a t i o n s ( n = 22 ;
Supplementary Fig. 4). The most common mutations





















First treatment after TAS-117  
Second treatment after TAS-117
Fourth treatment after TAS-117
Death
NGS time points
Initial cancer diagnosis   
Prior to TAS-117
Cancer (PI3K/AKT mutations)
Fig. 2 Swimmer plot depicting progression-free survival (PFS). All pa-
tients harbored PI3K aberrations, except for one patient with breast cancer
harboring Akt E17K*. Abbreviations: RECIST, response evaluation









































Fig. 3 Analysis of progression-
free survival (PFS) and overall
survival (OS). (a) PFS 1 (prior to
TAS-117), PFS 2 (TAS-117), and
PFS 3 (after TAS − 117). (b)
OS. Abbreviations: mPFS, medi-
an progression-free survival; OS,
overall survival, CI, confidence
interval; mo., months
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7), including missense mutations (n = 5), frameshift dele-
tion (n = 1), and frameshift insertion (n = 1). There were
no statistically significant correlations with regard to the
site of biopsy (primary vs. metastatic), biopsy time period
(initial cancer diagnosis vs. prior to TAS-117 treatment),
response evaluation according RECIST criteria (partial re-
sponse, PR; stable disease, SD; progressive disease, PD),
or tumor type (Supplementary Fig. 5).
Safety
AEs were evaluated in all 13 patients (Supplementary
Table S8). Treatment-related AEs are listed in Table 2.
Overall, 11 patients (85 %) experienced ≥ 1 treatment-
related AEs, including hyperglycemia (all grades, n = 4,
36 %), skin rash (all grades, n = 4, 36 %), anorexia (all
grades, n = 4, 36 %), nausea (all grades, n = 2, 15 %),
and diarrhea (all grades, n = 2, 15 %). Notably, two pa-
tients (15 %) experienced grade 3 (n = 1, 8 %) and grade
4 hyperglycemia (n = 1, 8 %; Supplementary Table S9).
Patients who were scheduled to receive dose reductions
progressed radiologically and discontinued treatment. One
patient experienced grade 3 anorexia (n = 1, 8 %), which
was well managed with supportive care. The median dose
intensity for TAS-117 was 100 % for both cohorts 1 and 2
(Supplementary Table S2, Figure S6). No patient death
occurred as a result of treatment-related AEs.
Some of the percentages are rounded up or down and may
not equal in sums.
Discussion
Preliminary results of an all-comers phase 1 study of TAS-117 in
62 patients with advanced solid tumors showed that among 20
patients with ovarian clear cell carcinoma, five (25%) experi-
enced > 30% tumor shrinkage and three (15%) showed an on-
going response [14]. Similarly, our study showed that one of the
four patients with ovarian cancer (25%) achieved a partial re-
sponse. This response, however, was not durable, and the patient
showed disease progression at 18 weeks, which did not correlate
with tumor markers. The other 12 patients, including those with
SD, showed radiological disease progression. Ten patients expe-
rienced initial radiological progression at 6 weeks, and two pa-
tients showed clinical progression before completing the first
treatment cycle. Overall, the short PFS and non-significant PFS
ratios observed reflected the minimal benefits of administering
TAS-117 as monotherapy. The main reasons for the recommen-
dations by the independent data monitoring committee to termi-
nate this study early and develop future combinations as earlier
treatment lines were the (1) lack of durable response to TAS-117
in heavily treated patients with diverse cancer types who were
refractory to standard treatments and (2) low accrual rate attrib-
uted to the low frequency of PI3K/Akt gene aberrations.
The lack of response to TAS-117 was attributed to several
factors. First, Akt inhibition alone is insufficient in targeting the
PI3K/Akt/mTOR pathway, as this shows various alterations
[18]. Studies have shown intrinsic feedback regulation and ac-
quired resistance mechanisms to PI3K inhibitors directly via ca-
nonical effectors of the pathway or parallel pathways that
crosstalk with this signaling cascade [19]. To block other
Table 2 Incidence of treatment-
related adverse events Treatment-related adverse events Grade 1 Grade 2 Grade 3 Grade 4 All grades
Any event 7 (54%) 17 (100%) 2 (15%) 1 (8%) 27 (100%)
Anorexia 1 (8%) 2 (15%) 1 (8%) 0 (0%) 4 (36%)
Constipation 0 (%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Diarrhea 1 (8%) 1 (8%) 0 (0%) 0 (0%) 2 (15%)
Nausea 1 (8%) 1 (8%) 0 (0%) 0 (0%) 2 (15%)
Mucositis 1 (8%) 0 (0%) 0 (0%) 0 (0%) 1 (8%)
Skin rash 2 (15%) 2 (15%) 0 (0%) 0 (0%) 4 (36%)
Itching 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Fatigue 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Headache 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Back pain 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Shoulder pain 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Dyspnea 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Pneumonia 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Pulmonary thromboembolism 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Hyperglycemia 1 (8%) 1 (8%) 1 (8%) 1 (8%) 4 (36%)
Neutropenia 0 (0%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
NOTE. Adverse events were those with onset after enrolment to last follow-up after disease progression
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compensatory signaling pathways and increase antitumor activi-
ties, the administration of a combination of targeted treatments
may be a feasible option. However, drugs co-targeting this path-
way show similar toxicities, thus making the development of
treatment combinations difficult [20]. For instance, buparlisib, a
pan-class 1 PI3K inhibitor, shows high toxicity with adverse
effects such as depression and anxiety, rendering its use inade-
quate in clinical settings [10]. Similarly, dual pan-PI3K and
mTOR inhibitors have also shown high toxicity levels, and their
development was discontinued [21].
Concurrent treatment with chemotherapy or immunotherapy
without overlapping toxicities may optimize the inhibition of the
PI3K/Akt/mTORpathway [19]. Notably, PI3K andAkt inhibitor
combinations have shown efficacy, especially in the treatment of
breast cancer. Understanding the mechanisms linking estrogen
receptor (ER) and the PI3K pathway has paved the way for
combination treatment using fulvestrant (ER antagonist) and
alpelisib, which shows synergistic antitumor activity in patients
with PIK3CA-mutated, ER-positive, HER2-negative, advanced
breast cancer unresponsive to previous estrogen therapy [9]. The
loss of PTEN has also been associated with resistance to T-cell–
mediated immunotherapy, and the combination of immunother-
apy with PI3K/Akt/mTOR pathway inhibitors may be a promis-
ing treatment option [22]. A first-line triplet regimen comprising
ipatasertib, an oral ATP-competitive Akt inhibitor, atezolizumab,
a programmed death-ligand 1 (PD-L1), and a chemotherapy
agent, is currently under investigation in metastatic triple-
negative breast cancer [23]. Furthermore, first-line treatment with
ipatasertib and abiraterone acetate improves radiographic PFS in
metastatic castration-resistant prostate cancer with PTEN loss
[24]. In this study, however, we were unable to identify de novo
co-existing mutations correlated with responses to TAS-117.
Second, there are currently no standardized, reliable predictive
biomarkers to select patients who can undergo treatment with
agents targeting the PI3K/Akt/mTORpathway. A previous study
showed that PIK3CA gene mutations predict responses or
prolonged PFS, but contradictory results were also observed
[18]. Other clinical models have shown that cells with a loss of
PTEN expression are more sensitive to Akt/PI3K inhibitors [25].
However, the definition and assessment of PTEN status via im-
munohistochemistry using different antibodies poses challenges
for both patient selection and biomarker analysis [26]. Other
preclinical data have shown that AktE17mutationmay be a useful
biomarker, but further proof-of-concept studies are required [27].
In preclinical settings, TAS-117was sensitive to Akt2 andHER2
gene amplification, PI3K mutation, and PTEN loss.
Nevertheless, none of the patients in our study showed concom-
itant Akt2 amplification and PTEN loss. One patient with breast
cancer harboring the PI3KCA H1047R mutation also showed
HER2 amplification but experienced no clinical response.
The mutation most commonly identified was a TP53 mis-
sense mutation, which was observed in five patients. Among
the two patients with breast cancer who achieved SD, one
harbored an Akt1E17Kmutation with a CDH1 frameshift deletion
and another harbored aPIK3CAH1047Rmutationwith aKRAS
missense mutation. The co-occurrence of TP53 and PIK3CA
mutations is commonly observed in breast cancers. However,
there is currently no evidence supporting the hypothesis that
tumors enriched with these mutations benefit more from treat-
ment with agents targeting the PI3K/Akt/mTOR pathway [28].
Similarly, CDH1 and PIK3CA have been commonly identified
in invasive lobular breast carcinoma [29], but whether these con-
current mutations are sensitive to PI3K/Akt/mTOR agents re-
mains to be confirmed. To our knowledge, there is no document-
ed evidence showing that the combination of KRAS missense
and PIK3CA H1047R mutations shows clinical relevance in
breast cancer. Overall, there were no identifiable PI3K/Akt aber-
rations showing specific responses to TAS-117. A deeper geno-
mic analysis will be prepared in a separate manuscript.
Finally, tumor types vary in terms of the duration and depth of
responses to agents targeting the PI3K/Akt/mTOR pathway ac-
cording to the degree of oncogenic addiction [30]. For some
cancer types, a PIK3CAmutation may just be a subclonal driver
mutation [31]. PIK3CA mutations have been commonly ob-
served in many different solid tumors, and their responses vary
across subtypes of PI3K [32]. Nonetheless, everolimus and
alpelisib, in combination with other agents, are the only drugs
to have shown clinical efficacy in breast cancer [6, 9], while
temsirolimus is the only drug to have shown clinical efficacy in
renal cell cancer [4]. Comparatively, other cancer types, such as
rectal cancer, do not benefit from treatment with agents inhibiting
this pathway [33]. Therefore, the proper selection of tumor types
as well as driver mutations that oncogenically activate the
PI3K/Akt/mTOR pathway is essential in achieving the full po-
tential of PI3K/Akt/mTOR inhibitors.
In this single-center phase 2 trial of multiple solid tumors
harboring PI3K/Akt aberrations, TAS-117 was well tolerated.
AEs of special interest such as skin rash (all grades, n = 4,
36%) and hyperglycemia (grade 3, n = 1, 8%; grade 4, n = 1,
8%) were well managed with dose interruption and supportive
care. Patients who experienced hyperglycemia did not require
dose reductions because they showed radiological progression
before resuming treatment. The lack of AEs may be attributed
to insufficient exposure to TAS-117. TAS-117 showed efficacy
in one patient with ovarian cancer and disease control in two
patients with breast cancer, suggesting specific histology and
genotype preference; nonetheless, the short PFS suggests activa-
tion of collateral resistance pathways.However, our study did not
require mandatory re-biopsy after treatment failure for the eval-
uation of adaptive resistance mechanisms.
Conclusions
TAS-117 showed limited antitumor activity and a manageable
toxicity profile in patients with diverse advanced solid tumors.
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Clinical efficacy was observed in patients with ovarian cancer
(PIK3CA E545K mutation) and breast cancer (PIK3CA
H1047R and Akt1E17K mutations). De novo resistance to
TAS-117 can be overcome by administering a combination
treatment comprising chemotherapy, targeted therapy, and im-
munotherapy and including TAS-117 in earlier treatment lines
in patients with breast and ovarian cancers to target PIK3CA
E545K, H1047R, and Akt1E17K mutations.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s10637-021-01085-7.
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